Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
Pubmed

Nuclear Functions of Nucleolin through Global Proteomics and Interactomic Approaches.

CEP170 TSR1 H1-10 MYBBP1A ILF3

4.69e-0814524527049334
Pubmed

An atlas of combinatorial transcriptional regulation in mouse and man.

SSX5 RFX5 H1-10 SCMH1 ANKRD55 MYBBP1A MLLT10

1.51e-0687724720211142
Pubmed

STING-Mediated IFI16 Degradation Negatively Controls Type I Interferon Production.

TSR1 H1-10 MYBBP1A ILF3 SPATS2L

2.21e-0631624531665637
Pubmed

Characterization of the DOT1L network: implications of diverse roles for DOT1L.

RFX5 H1-10 MLLT10

3.03e-064124320431927
Pubmed

WWP2 ubiquitylates RNA polymerase II for DNA-PK-dependent transcription arrest and repair at DNA breaks.

TSR1 H1-10 PALLD MYBBP1A ILF3 SPATS2L

3.06e-0661524631048545
Pubmed

GRWD1 regulates ribosomal protein L23 levels via the ubiquitin-proteasome system.

CEP170 H1-10 MYBBP1A ILF3

1.53e-0522124429991511
Pubmed

Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery.

TSR1 H1-10 MYBBP1A ILF3

1.58e-0522324420020773
Pubmed

Proteomic analysis of human Nop56p-associated pre-ribosomal ribonucleoprotein complexes. Possible link between Nop56p and the nucleolar protein treacle responsible for Treacher Collins syndrome.

H1-10 MYBBP1A ILF3

1.67e-057224312777385
Pubmed

Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.

CEP170 TSR1 H1-10 MYBBP1A ILF3

1.78e-0548624530940648
Pubmed

FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2.

CEP170 TSR1 H1-10 MYBBP1A SPATS2L

4.91e-0560124533658012
Pubmed

Characterization of gene regulation and protein interaction networks for Matrin 3 encoding mutations linked to amyotrophic lateral sclerosis and myopathy.

TSR1 MYBBP1A ILF3

5.78e-0510924329511296
Pubmed

Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication.

H1-10 MYBBP1A ILF3

7.88e-0512124334029587
Pubmed

PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.

TSR1 H1-10 MYBBP1A ILF3 SPATS2L

8.67e-0567824530209976
Pubmed

The functional interactome of PYHIN immune regulators reveals IFIX is a sensor of viral DNA.

TSR1 H1-10 MYBBP1A SPATS2L

9.04e-0534924425665578
Pubmed

BPA modulates the WDR5/TET2 complex to regulate ERβ expression in eutopic endometrium and drives the development of endometriosis.

TSR1 H1-10 MYBBP1A ILF3 SPATS2L

1.08e-0471124533022573
Pubmed

RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease.

CEP170 TSR1 H1-10 MYBBP1A ILF3

1.10e-0471324529802200
Pubmed

Assessment of a polymorphism of SDK1 with hypertension in Japanese Individuals.

DNAJC6 PLA2G3 LLGL2

1.27e-0414224319851296
Pubmed

Association of genetic variants with hemorrhagic stroke in Japanese individuals.

DNAJC6 PLA2G3 LLGL2

1.29e-0414324320198315
Pubmed

Identification of a USP9X Substrate NFX1-123 by SILAC-Based Quantitative Proteomics.

TSR1 H1-10 MYBBP1A ILF3

1.31e-0438424431059266
Pubmed

Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.

CEP170 TSR1 H1-10 MYBBP1A ILF3 SPATS2L

1.69e-04125724636526897
Pubmed

The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain.

TSR1 H1-10 ILF3 SPATS2L

1.79e-0441724436537216
Pubmed

Wnt regulation: exploring Axin-Disheveled interactions and defining mechanisms by which the SCF E3 ubiquitin ligase is recruited to the destruction complex.

CEP170 TSR1 H1-10 MYBBP1A ILF3

1.98e-0480924532129710
Pubmed

Comparative Proteomics and Interactome Analysis of the SARS-CoV-2 Nucleocapsid Protein in Human and Bat Cell Lines.

TSR1 H1-10 ILF3

2.08e-0416824339066279
Pubmed

The cooperative action of CSB, CSA, and UVSSA target TFIIH to DNA damage-stalled RNA polymerase II.

TSR1 H1-10

2.10e-043124232355176
Pubmed

Targeted and Interactome Proteomics Revealed the Role of PHD2 in Regulating BRD4 Proline Hydroxylation.

CEP170 TSR1 H1-10 ILF3

2.22e-0444124431239290
Pubmed

Identification of proximal SUMO-dependent interactors using SUMO-ID.

CEP170 PALLD ILF3 SENP5

2.27e-0444424434795231
Pubmed

Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.

TSR1 H1-10 MYBBP1A ILF3 SPATS2L

2.45e-0484724535850772
Pubmed

CYLD Regulates Centriolar Satellites Proteostasis by Counteracting the E3 Ligase MIB1.

CEP170 PALLD ILF3

2.63e-0418224331067453
Pubmed

Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.

CEP170 RFX5 PALLD

2.72e-0418424332908313
Pubmed

Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF).

TSR1 H1-10 MYBBP1A

3.03e-0419124321907836
Pubmed

Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones.

CEP170 TSR1 H1-10 PALLD MYBBP1A ILF3

3.21e-04141524628515276
Pubmed

TBK1 phosphorylation activates LIR-dependent degradation of the inflammation repressor TNIP1.

TSR1 H1-10 MYBBP1A LLGL2 ILF3

4.13e-0494924536574265
Pubmed

Comprehensive interactome profiling of the human Hsp70 network highlights functional differentiation of J domains.

DNAJC6 TSR1 H1-10 FRAS1 MYBBP1A ILF3

4.19e-04148724633957083
Pubmed

The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.

CEP170 RFX5 H1-10 MYBBP1A ILF3

4.23e-0495424536373674
Pubmed

Proteome analysis of the HIV-1 Gag interactome.

MYBBP1A ILF3

4.24e-044424225010285
Pubmed

PTENα and PTENβ promote carcinogenesis through WDR5 and H3K4 trimethylation.

CEP170 MYBBP1A ILF3

4.40e-0421724331685992
Pubmed

GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ERα glycosylation and stability to cancer.

H1-10 MYBBP1A ILF3

4.77e-0422324333731348
Pubmed

Arginine methylation and ubiquitylation crosstalk controls DNA end-resection and homologous recombination repair.

CEP170 H1-10 MYBBP1A ILF3

5.15e-0455124434728620
Pubmed

SARS-CoV-2 N Protein Antagonizes Stress Granule Assembly and IFN Production by Interacting with G3BPs to Facilitate Viral Replication.

H1-10 ILF3 SPATS2L

6.26e-0424524335652658
Pubmed

Characterization of cDNA clones in size-fractionated cDNA libraries from human brain.

CEP170 DNAJC6

6.87e-04562429455484
InteractionPSPC1 interactions

CEP170 TSR1 H1-10 MYBBP1A ILF3 SPATS2L

1.42e-05515226int:PSPC1
InteractionRPS19 interactions

TSR1 RFX5 H1-10 MYBBP1A ILF3 SPATS2L

4.80e-05639226int:RPS19
InteractionRPL10 interactions

TSR1 H1-10 ANKRD55 FRAS1 MYBBP1A ILF3

8.09e-05702226int:RPL10
InteractionDNAJC2 interactions

TSR1 H1-10 MYBBP1A ILF3

8.21e-05217224int:DNAJC2
InteractionIFI16 interactions

CEP170 TSR1 H1-10 MYBBP1A ILF3 SPATS2L

8.88e-05714226int:IFI16
InteractionZNF668 interactions

MYBBP1A LLGL2 ILF3 SPATS2L

9.61e-05226224int:ZNF668
InteractionMBD6 interactions

H1-10 MYBBP1A ILF3

1.29e-0491223int:MBD6
InteractionCBX8 interactions

TSR1 H1-10 SCMH1 ILF3

1.40e-04249224int:CBX8
InteractionNCL interactions

CEP170 TSR1 H1-10 ANKRD55 MYBBP1A ILF3

1.64e-04798226int:NCL
InteractionDOT1L interactions

TSR1 H1-10 MYBBP1A ILF3 SPATS2L MLLT10

1.74e-04807226int:DOT1L
InteractionWWP2 interactions

TSR1 H1-10 PALLD MYBBP1A ILF3 SPATS2L

2.16e-04840226int:WWP2
InteractionRPS24 interactions

TSR1 H1-10 MYBBP1A ILF3 SPATS2L

2.22e-04529225int:RPS24
InteractionNOP56 interactions

TSR1 H1-10 ANKRD55 MYBBP1A ILF3

3.14e-04570225int:NOP56
InteractionH3C1 interactions

TSR1 RFX5 H1-10 PALLD MYBBP1A SPATS2L

3.16e-04901226int:H3C1
Cytoband22q12.2

SFI1 PLA2G3

4.25e-045824222q12.2
Cytoband17p13.3

TSR1 MYBBP1A

9.75e-048824217p13.3
CytobandEnsembl 112 genes in cytogenetic band chr22q12

SFI1 PLA2G3

6.69e-03235242chr22q12
CoexpressionGSE21033_3H_VS_24H_POLYIC_STIM_DC_UP

DNAJC6 SCMH1 LLGL2 SPATS2L MLLT10

2.94e-07166235M7722
CoexpressionGSE20500_CTRL_VS_RARA_ANTAGONIST_TREATED_CD4_TCELL_UP

CEP170 SCMH1 PLA2G3 LLGL2

2.35e-05195234M7706
ToppCellpdx|World / Sample and Cell Type and Tumor Cluster (all cells)

SCMH1 FRAS1 LLGL2 SPATS2L

2.82e-06186244de8e538c8767d41b8a52f5e58ba1affd4e7244c4
ToppCellpdx-Tumor_cells|World / Sample and Cell Type and Tumor Cluster (all cells)

SCMH1 FRAS1 LLGL2 SPATS2L

2.82e-061862440b88a87158a9ca8de3bf40a4ff1687150707a5f0
DrugBW-B 70C; Up 200; 31.6uM; MCF7; HT_HG-U133A_EA

DNAJC6 PALLD ILF3 MLLT10

1.93e-051692241132_UP
DrugHomochlorcyclizine dihydrochloride [1982-36-1]; Up 200; 10.4uM; PC3; HT_HG-U133A

DNAJC6 MLLT10 PCDH12 SENP5

2.69e-051842247295_UP
DrugCarisoprodol [78-44-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A

TSR1 SFI1 PLA2G3 SENP5

3.25e-051932243251_UP
DrugPHA-00745360 [351320-33-7]; Up 200; 10uM; MCF7; HT_HG-U133A

FRAS1 SFI1 PLA2G3 PCDH12

3.45e-051962243907_UP
DrugDimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; HL60; HT_HG-U133A

TESMIN ANO2 PALLD FRAS1

3.52e-051972242151_UP
DrugAG-028671 [847803-03-6]; Down 200; 10uM; MCF7; HT_HG-U133A

TSR1 MYBBP1A SFI1 PLA2G3

3.59e-051982246587_DN
DrugAmiprilose hydrochloride [60414-06-4]; Down 200; 11.8uM; HL60; HT_HG-U133A

SFI1 PLA2G3 MLLT10 PCDH12

3.59e-051982243000_DN
Drug15d-PGJ2; Up 200; 10uM; HL60; HT_HG-U133A

DNAJC6 PALLD SPATS2L

5.58e-041692232691_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A

DNAJC6 H1-10 PALLD

5.58e-041692231793_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A

DNAJC6 H1-10 PALLD

6.17e-041752237245_UP
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A

DNAJC6 H1-10 SFI1

6.28e-041762234565_UP
Drugcerium

TESMIN ANO2

6.46e-0439222CID000008762
Drugtrichostatin A, Streptomyces sp.; Up 200; 1uM; PC3; HT_HG-U133A

DNAJC6 H1-10 SFI1

6.49e-041782235940_UP
DrugDihydroergotamine tartrate [5989-77-5]; Down 200; 3uM; HL60; HG-U133A

TSR1 MYBBP1A ILF3

6.59e-041792231398_DN
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A

DNAJC6 H1-10 PALLD

6.81e-041812235822_UP
DrugF0447-0125; Down 200; 10uM; PC3; HT_HG-U133A

H1-10 SFI1 MLLT10

7.14e-041842236429_DN
Drug15d-PGJ2; Down 200; 10uM; HL60; HT_HG-U133A

ANKRD55 MYBBP1A SFI1

7.48e-041872236190_DN
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A

DNAJC6 H1-10 PALLD

7.72e-041892232904_UP
DrugSeneciphylline [480-81-9]; Down 200; 12uM; MCF7; HT_HG-U133A

DNAJC6 MLLT10 SENP5

7.72e-041892232797_DN
DrugLY 294002; Down 200; 10uM; HL60; HT_HG-U133A

TSR1 ANKRD55 SPATS2L

7.72e-041892231168_DN
DrugAcacetin [480-44-4]; Down 200; 14uM; HL60; HT_HG-U133A

H1-10 SFI1 MLLT10

7.84e-041902232189_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

TSR1 ILF3 MLLT10

7.84e-041902236709_DN
DrugTetrahydrozoline hydrochloride [522-48-5]; Down 200; 16.8uM; MCF7; HT_HG-U133A

PLA2G3 PCDH12 SENP5

7.84e-041902236769_DN
DrugLY 294002; Up 200; 10uM; PC3; HT_HG-U133A

ANO2 SFI1 SENP5

7.96e-041912234451_UP
Drugwortmannin from Penicillium funiculosum; Down 200; 0.01uM; MCF7; HT_HG-U133A_EA

DNAJC6 MLLT10 SENP5

7.96e-041912231023_DN
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A

DNAJC6 PALLD SFI1

8.08e-041922233114_UP
DrugGlycocholic acid [475-31-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A

TSR1 SCMH1 MLLT10

8.32e-041942235316_DN
DrugRapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A

TSR1 SFI1 MLLT10

8.32e-041942236201_DN
DrugMetronidazole [443-48-1]; Down 200; 23.4uM; MCF7; HT_HG-U133A

SFI1 ILF3 SENP5

8.32e-041942234141_DN
DrugCP-690334-01 [459212-38-5]; Up 200; 10uM; MCF7; HT_HG-U133A

TESMIN PLA2G3 SENP5

8.32e-041942233906_UP
DrugThonzonium bromide [553-08-2]; Up 200; 6.8uM; MCF7; HT_HG-U133A

SFI1 PLA2G3 PCDH12

8.32e-041942236457_UP
DrugEnilconazole [35554-44-0]; Down 200; 13.4uM; MCF7; HT_HG-U133A

MYBBP1A SFI1 SENP5

8.32e-041942236518_DN
DrugEthoxyquin [91-53-2]; Up 200; 18.4uM; MCF7; HT_HG-U133A

TESMIN FRAS1 SFI1

8.32e-041942233846_UP
DrugHarmine hydrochloride [343-27-1]; Up 200; 16uM; PC3; HT_HG-U133A

ANO2 MLLT10 SENP5

8.32e-041942235855_UP
DrugGuaifenesin [93-14-1]; Down 200; 20.2uM; MCF7; HT_HG-U133A

PLA2G3 ILF3 MLLT10

8.32e-041942233431_DN
DrugLynestrenol [52-76-6]; Up 200; 14uM; HL60; HG-U133A

RFX5 ANKRD55 MLLT10

8.45e-041952232037_UP
DrugDiphenidol hydrochloride [3254-89-5]; Up 200; 11.6uM; MCF7; HT_HG-U133A

SFI1 MLLT10 PCDH12

8.45e-041952237406_UP
DrugMafenide hydrochloride [138-37-4]; Down 200; 18uM; HL60; HG-U133A

TSR1 SFI1 SENP5

8.45e-041952231441_DN
Drugprochlorperazine dimaleate salt; Down 200; 10uM; HL60; HT_HG-U133A

SFI1 MLLT10 SENP5

8.45e-041952236174_DN
DrugSuprofen [40828-46-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A

TESMIN ANKRD55 SFI1

8.45e-041952234123_UP
DrugMethoxy-6-harmalan [3589-73-9]; Down 200; 18.6uM; HL60; HG-U133A

TSR1 SCMH1 MLLT10

8.45e-041952231743_DN
DrugSpaglumic acid [4910-46-7]; Down 200; 13.2uM; HL60; HT_HG-U133A

ANKRD55 PALLD SFI1

8.45e-041952232962_DN
DrugBetazole hydrochloride; Down 200; 27uM; HL60; HT_HG-U133A

TSR1 ANKRD55 ILF3

8.58e-041962231854_DN
DrugAcacetin [480-44-4]; Up 200; 14uM; MCF7; HT_HG-U133A

TESMIN ANO2 MLLT10

8.58e-041962233849_UP
Drug(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Up 200; 12.2uM; HL60; HT_HG-U133A

TESMIN PALLD MLLT10

8.58e-041962232969_UP
Drug(S)-propranolol hydrochloride [4199-10-4]; Up 200; 13.6uM; HL60; HT_HG-U133A

TESMIN SFI1 MLLT10

8.58e-041962232961_UP
Drugnordihydroguaiaretic acid; Down 200; 1uM; HL60; HT_HG-U133A

MYBBP1A SPATS2L SENP5

8.58e-041962231164_DN
DrugSolanine alpha [20562-02-1]; Up 200; 4.6uM; PC3; HT_HG-U133A

PLA2G3 MLLT10 SENP5

8.58e-041962234087_UP
DrugDequalinium dichloride [522-51-0]; Up 200; 7.6uM; HL60; HT_HG-U133A

PALLD MLLT10 SENP5

8.58e-041962231276_UP
DrugFluvoxamine maleate [61718-82-9]; Up 200; 9.2uM; HL60; HT_HG-U133A

TESMIN ANO2 SFI1

8.58e-041962232913_UP
DrugTiapride hydrochloride [51012-33-0]; Up 200; 11uM; HL60; HT_HG-U133A

ANKRD55 MLLT10 SENP5

8.58e-041962232331_UP
DrugMethimazole [60-56-0]; Up 200; 35uM; MCF7; HT_HG-U133A

TESMIN FRAS1 PCDH12

8.58e-041962234372_UP
DrugNS-398; Up 200; 10uM; MCF7; HT_HG-U133A

SFI1 PLA2G3 MLLT10

8.58e-041962236911_UP
DrugAmyleine hydrochloride [532-59-2]; Down 200; 14.8uM; PC3; HG-U133A

TSR1 RFX5 H1-10

8.58e-041962231909_DN
DrugTocainide hydrochloride; Down 200; 17.4uM; HL60; HT_HG-U133A

PALLD LLGL2 MLLT10

8.70e-041972232931_DN
DrugCarbimazole [22232-54-8]; Down 200; 21.4uM; MCF7; HT_HG-U133A

MYBBP1A PLA2G3 SENP5

8.70e-041972233299_DN
DrugEstriol [50-27-1]; Up 200; 13.8uM; PC3; HT_HG-U133A

SFI1 PLA2G3 SENP5

8.70e-041972235866_UP
DrugTicarcillin sodium [4697-14-7]; Down 200; 9.4uM; MCF7; HT_HG-U133A

SCMH1 SFI1 ILF3

8.70e-041972237185_DN
DrugEquilin [474-86-2]; Down 200; 15uM; HL60; HT_HG-U133A

ANKRD55 SFI1 MLLT10

8.70e-041972233039_DN
DrugNicardipine hydrochloride [54527-84-3]; Down 200; 7.8uM; MCF7; HT_HG-U133A

SFI1 PLA2G3 MLLT10

8.70e-041972233215_DN
DrugHydroxytacrine maleate (R,S) [118909-22-1]; Up 200; 12.2uM; MCF7; HT_HG-U133A

ANO2 SFI1 PLA2G3

8.70e-041972234997_UP
DrugSuprofen [40828-46-4]; Down 200; 15.4uM; HL60; HT_HG-U133A

SFI1 PLA2G3 PCDH12

8.70e-041972233005_DN
DrugCiprofibrate [52214-84-3]; Down 200; 13.8uM; HL60; HT_HG-U133A

SFI1 LLGL2 SENP5

8.70e-041972236138_DN
DrugPempidine tartrate [546-48-5]; Up 200; 13uM; MCF7; HT_HG-U133A

DNAJC6 ANKRD55 ANO2

8.70e-041972233926_UP
DrugAmikacin hydrate [37517-28-5]; Up 200; 6.6uM; MCF7; HT_HG-U133A

SFI1 PLA2G3 SENP5

8.70e-041972235314_UP
DrugRamipril [87333-19-5]; Down 200; 9.6uM; MCF7; HT_HG-U133A

SCMH1 PLA2G3 SENP5

8.70e-041972233572_DN
DrugZalcitabine [7481-89-2]; Down 200; 19uM; MCF7; HT_HG-U133A

PLA2G3 MLLT10 SENP5

8.70e-041972237352_DN
DrugHarmol hydrochloride monohydrate [40580-83-4]; Down 200; 15.8uM; HL60; HG-U133A

H1-10 SCMH1 MYBBP1A

8.70e-041972231750_DN
Drug0173570-0000 [211245-44-2]; Up 200; 1uM; PC3; HT_HG-U133A

RFX5 SFI1 PLA2G3

8.70e-041972233693_UP
DrugICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A

TESMIN MLLT10 PCDH12

8.70e-041972235964_UP
DrugOxalamine citrate salt [1949-20-8]; Down 200; 9.2uM; HL60; HT_HG-U133A

SFI1 PCDH12 SENP5

8.70e-041972233006_DN
Drug2-propylpentanoic acid; Down 200; 50uM; HL60; HT_HG-U133A

MYBBP1A SFI1 MLLT10

8.70e-041972236181_DN
DrugAmprolium hydrochloride [137-88-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A

TSR1 SCMH1 ILF3

8.83e-041982234825_DN
DrugTriamterene [396-01-0]; Up 200; 15.8uM; HL60; HT_HG-U133A

SFI1 MLLT10 PCDH12

8.83e-041982231861_UP
Drugchlorpromazine hydrochloride; Down 200; 1uM; MCF7; HG-U133A

TSR1 SFI1 MLLT10

8.83e-04198223426_DN
DrugLaudanosine (R,S) [1699-51-0]; Up 200; 11.2uM; MCF7; HT_HG-U133A

ANKRD55 FRAS1 SFI1

8.83e-041982232890_UP
DrugChlorprothixene hydrochloride [6469-93-8]; Up 200; 11.4uM; HL60; HT_HG-U133A

PALLD SFI1 SENP5

8.83e-041982231272_UP
DrugPinacidil [85371-64-8]; Up 200; 16.4uM; MCF7; HT_HG-U133A

DNAJC6 SCMH1 PCDH12

8.83e-041982237437_UP
DrugPhenformin hydrochloride [834-28-6]; Up 200; 16.6uM; MCF7; HT_HG-U133A

TESMIN ANKRD55 ANO2

8.83e-041982232312_UP
DrugViomycin sulfate [37883-00-4]; Up 200; 5.2uM; HL60; HT_HG-U133A

TESMIN SFI1 MLLT10

8.83e-041982232979_UP
DrugIobenguane sulfate; Up 200; 10.8uM; PC3; HT_HG-U133A

DNAJC6 SFI1 MLLT10

8.83e-041982237299_UP
Drugfluphenazine dihydrochloride; Up 200; 10uM; HL60; HT_HG-U133A

SFI1 MLLT10 SENP5

8.83e-041982231178_UP
DrugTiabendazole [148-79-8]; Up 200; 19.8uM; HL60; HT_HG-U133A

TESMIN DNAJC6 PALLD

8.83e-041982232479_UP
DrugEtofylline [519-37-9]; Up 200; 17.8uM; MCF7; HT_HG-U133A

TESMIN FRAS1 SFI1

8.83e-041982232256_UP
Drug(+) -Levobunolol hydrochloride [47141-41-3]; Down 200; 12.2uM; HL60; HT_HG-U133A

SFI1 PLA2G3 MLLT10

8.83e-041982233016_DN
DrugFlufenamic acid [530-78-9]; Down 200; 14.2uM; PC3; HT_HG-U133A

SFI1 MLLT10 SENP5

8.83e-041982235059_DN
DrugIsoxicam [34552-84-6]; Down 200; 12uM; HL60; HT_HG-U133A

ANKRD55 MYBBP1A SPATS2L

8.83e-041982231862_DN
DrugViomycin sulfate [37883-00-4]; Up 200; 5.2uM; MCF7; HT_HG-U133A

ANKRD55 ANO2 SFI1

8.96e-041992233541_UP
DrugBacampicillin hydrochloride [37661-08-8]; Up 200; 8uM; MCF7; HT_HG-U133A

H1-10 SFI1 PLA2G3

8.96e-041992233273_UP
DrugGraveoline [485-61-0]; Up 200; 14.4uM; HL60; HT_HG-U133A

TESMIN PLA2G3 PCDH12

8.96e-041992232179_UP
DrugGibberellic acid [77-06-5]; Up 200; 11.6uM; PC3; HT_HG-U133A

ANO2 SFI1 PLA2G3

8.96e-041992234234_UP
DrugCeftazidime pentahydrate [78439-06-2]; Down 200; 6.2uM; MCF7; HT_HG-U133A

SCMH1 PLA2G3 MLLT10

8.96e-041992235473_DN
DrugLymecycline [992-21-2]; Up 200; 6.6uM; HL60; HT_HG-U133A

TESMIN SFI1 MLLT10

8.96e-041992232953_UP
DrugThiethylperazine malate [52239-63-1]; Down 200; 6uM; PC3; HT_HG-U133A

MYBBP1A SFI1 MLLT10

8.96e-041992235756_DN
DrugLetrozole [112809-51-5]; Up 200; 14uM; MCF7; HT_HG-U133A

DNAJC6 SFI1 SENP5

8.96e-041992237336_UP
DrugThyroxine (L) [51-48-9]; Up 200; 5.2uM; MCF7; HT_HG-U133A

TSR1 SFI1 PLA2G3

8.96e-041992233249_UP
DrugPD184352

PALLD ILF3

8.99e-0446222CID006918454
DrugPyrazinamide [ 98-96-4]; Up 200; 32.4uM; PC3; HT_HG-U133A

ANO2 PLA2G3 MLLT10

9.09e-042002236617_UP
DrugIodipamide [606-17-7]; Down 200; 3.6uM; MCF7; HT_HG-U133A

MYBBP1A MLLT10 SENP5

9.09e-042002235510_DN
DrugMoxisylyte hydrochoride [964-52-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A

DNAJC6 SCMH1 MLLT10

9.09e-042002237015_DN
Diseaserheumatoid arthritis, ACPA-positive rheumatoid arthritis, rheumatoid factor seropositivity measurement

ANKRD55 ILF3

1.10e-0363232EFO_0000685, EFO_0007791, EFO_0009459
Diseasesodium measurement

ANKRD55 MLLT10

2.91e-03103232EFO_0009282
Diseaseforced expiratory volume

SCMH1 LLGL2 ILF3 SPATS2L

3.00e-03789234EFO_0004314
DiseasePapillary Renal Cell Carcinoma

MLLT10 MSGN1

4.45e-03128232C1306837
DiseaseRenal Cell Carcinoma

MLLT10 MSGN1

4.45e-03128232C0007134
DiseaseSarcomatoid Renal Cell Carcinoma

MLLT10 MSGN1

4.45e-03128232C1266043
DiseaseChromophobe Renal Cell Carcinoma

MLLT10 MSGN1

4.45e-03128232C1266042
DiseaseCollecting Duct Carcinoma of the Kidney

MLLT10 MSGN1

4.45e-03128232C1266044
DiseaseConventional (Clear Cell) Renal Cell Carcinoma

MLLT10 MSGN1

5.90e-03148232C0279702
DiseaseParoxysmal atrial fibrillation

SCMH1 SPATS2L

6.53e-03156232C0235480
DiseasePersistent atrial fibrillation

SCMH1 SPATS2L

6.53e-03156232C2585653
Diseasefamilial atrial fibrillation

SCMH1 SPATS2L

6.53e-03156232C3468561
DiseaseAtrial Fibrillation

SCMH1 SPATS2L

6.86e-03160232C0004238
Diseaseserum IgG glycosylation measurement

ANKRD55 MARCOL ANO2

7.53e-03523233EFO_0005193
Diseaseurinary albumin to creatinine ratio

SPATS2L MLLT10

8.52e-03179232EFO_0007778

Protein segments in the cluster

PeptideGeneStartEntry
RGGHGVPHGKLLKQK

CEP170

431

Q5SW79
NGAKHNIPDKNGRLP

ANKRD55

116

Q3KP44
RGGQGPKHGQQCLKM

ANO2

26

Q9NQ90
PKNGLENPEGGAHKK

RFX5

266

P48382
PKPNHRGNKYLAKPG

PCDH12

976

Q9NPG4
QPTHLQGGGGPKAQK

MSGN1

101

A6NI15
GPKHGFVENKLQPGR

FRAS1

2486

Q86XX4
KNHRPGNGAGPKKAP

LLGL2

941

Q6P1M3
PARGQKPEQRSHKKG

H1-10

161

Q92522
PAGQKQHQKALPKKG

MYBBP1A

1271

Q9BQG0
PGEKHQPKGKPIANG

FADS2B

21

A8MWK0
NVKPKTPHQRKGGPQ

PALLD

151

Q8WX93
VPPKHAGKKQPHGGQ

ILF3

726

Q12906
PHGNANGDKPHGVKK

DNAJC6

466

O75061
QPKIGKGQLGNVKPQ

TESMIN

351

Q9Y4I5
KQKVLGRGGKPQPLA

SFI1

931

A8K8P3
HNGFRPKNKGGAKNQ

SPATS2L

476

Q9NUQ6
QQGKPGLSSHQGKPG

MARCOL

236

A0A1B0GUY1
GPPHQKGSKRPSKAN

PLA2G3

311

Q9NZ20
LEHQPGQRGRKPGKK

SCMH1

266

Q96GD3
NKQSKHGPGRPKGNK

MLLT10

471

P55197
HGPGRPKGNKNQENV

MLLT10

476

P55197
HRNGGPLIPKKFQLN

SENP5

206

Q96HI0
PGPLKQQNKAHKGGR

TSR1

6

Q2NL82
GPQNNGKQLRPSGKL

SSX5

131

O60225